Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775722 | 0.92 | GSK3B (0.41) | GSK3BS1PR1S1PR3SMN1; SMN2GPBAR1 | |
| SCHEMBL5771831 | 0.92 | HDAC8 (0.34) | GSK3BSLC2A1HDAC8NAMPT | |
| SCHEMBL5774478 | 0.91 | HIF1A (0.42) | S1PR1SMN1; SMN2GPBAR1NR1H2NR1H3 | |
| SCHEMBL5773874 | 0.85 | MAPT (0.42) | SMN1; SMN2FAAHNAMPT | |
| SCHEMBL5774573 | 0.85 | LMNA (0.40) | GSK3BHDAC1HDAC2HDAC8TRPV1 | |
| SCHEMBL5771105 | 0.85 | GSK3B (0.39) | GSK3BS1PR1S1PR3SMN1; SMN2HDAC1 | |
| SCHEMBL5773577 | 0.84 | NAMPT (0.35) | GSK3BHDAC1HDAC8NAMPT | |
| SCHEMBL5776662 | 0.84 | TRPV1 (0.37) | SMN1; SMN2GPBAR1HDAC1HDAC2HDAC8 | |
| SCHEMBL5771107 | 0.82 | HDAC4 (0.35) | S1PR1SMN1; SMN2HDAC1HDAC2HDAC8 | |
| SCHEMBL5774056 | 0.82 | TRPV1 (0.38) | HDAC1HDAC2HDAC8TRPV1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | GSK3B 1517/4885S1PR1 3313/4885S1PR3 1669/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | GSK3B 2013/4885S1PR1 3402/4885S1PR3 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.